Effects of triple therapy in IgA nephritis: a follow-up study 5 years later.
This study is a 5-year post trial assessment of patients with IgA nephritis who entered a 3-year prospective controlled trial of cyclophosphamide, dipyridamole (D) and low-dose warfarin (W). Patients entered the trial from 1979 to 1981 and the trial ended in 1984 with those in the treatment group having more stable renal function and less proteinuria compared to the control group. Present reassessment of the patients in 1989 showed no difference in the renal function between those in the treatment group (n = 27) and the control group (n = 21). 6 patients in the treatment group and 7 in the control group were in ESRF. At the conclusion of the trial in 1984, among the 27 patients in the original treatment group, 13 patients elected to continue with D + W while the other 14 patients chose to cease therapy and therefore served as the new control group. 5 years later, renal function in the new treatment group (n = 13) was significantly stable compared to the new control group (n = 14), (serum creatinine 1.4 +/- 0.7 versus 4.4 +/- 3.2 mg/dl, p less than 0.01). Furthermore, all the 6 patients with ESRF in the original treatment group of 27 patients were from the new control group (n = 14) where treatment with D + W had been ceased. None of the patients still on D + W are in ESRF.
Woo
K T
KT
Department of Renal Medicine, Singapore General Hospital.
Lee
G S
GS
Lau
Y K
YK
Chiang
G S
GS
Lim
C H
CH
D000328:Adult; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004176:Dipyridamole / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005922:Glomerulonephritis, IGA / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D007677:Kidney Function Tests; D008297:Male; D011446:Prospective Studies; D013997:Time Factors; D014859:Warfarin / Q000627:therapeutic use*
D014859:Warfarin; D004176:Dipyridamole; D003520:Cyclophosphamide